-
In April, the listed company's repurchase enthusiasm was high, and this pharmaceutical company plans to repurchase more than 1.1 billion yuan
Time of Update: 2022-05-19
11942 billion yuan of its own funds to repurchase the company's shares for the implementation of employee stock ownership plans or equity incentive plans .
-
Xinlitai HFpEF drug SAL007 clinical trial application accepted
Time of Update: 2022-05-19
The application submitted by the company this time is a Phase I clinical trial application of SAL007 for the indication of HFpEF (heart failure with preserved ejection fraction) in chronic heart failure .
-
BeiGene's TYK2 inhibitor starts clinical trials in China
Time of Update: 2022-05-19
Among them, Deucravicitinib of BMS is a first-in-class oral TYK2 inhibitor, and five phase III clinical trials have been launched in China; a new drug marketing application has been submitted to the US FDA in November last year, and it is expected to be approved in September this year .
-
The pharmaceutical industry performed well in the first quarter, with the added value increasing by 11.8% year-on-year
Time of Update: 2022-05-19
Among them, Tonghua Dongbao expects to achieve a net profit of 817 million yuan attributable to shareholders of listed companies in the first quarter, a year-on-year increase of 142.
-
The State Food and Drug Administration released the results of medical device supervision and sampling inspection of 12 batches (sets) of unqualified products
Time of Update: 2022-05-19
On April 20, the State Food and Drug Administration issued an announcement stating that in order to strengthen the supervision and management of medical devices and ensure the quality, safety and effectiveness of medical device products, the State Food and Drug Administration organized five varieties of intervertebral fusion cages and semiconductor laser treatment machines.
-
A variety of parenteral nutrition therapy drugs have been approved one after another, and the market of 10 billion yuan will be in waves
Time of Update: 2022-05-19
Coincidentally, Kelun Pharmaceutical also issued two consecutive announcements recently, stating that the company's medium and long chain fat emulsion/amino acid (16)/glucose (36%) injection and medium and long chain fat emulsion/amino acid (16)/glucose (30%) %) injection was approved on the same day as the imitation class 3, which is regarded as over-evaluation.
-
Haisco Fat Emulsion Amino Acid (17) Glucose (11%) Injection Review
Time of Update: 2022-05-19
On April 19, Haisco announced that the company's subsidiary, Liaoning Haisco Pharmaceuticals Fat Emulsion Amino Acid (17) Glucose (11%) Injection passed the quality and efficacy consistency evaluation of generic drugs .
-
Connoya's Claudin 18.2 ADC Receives FDA Fast Track Designation for Gastric Cancer
Time of Update: 2022-05-19
Previously, Connoya has obtained FDA approval for CMG901 clinical trials in gastric cancer and gastroesophageal junction adenocarcinoma in the United States in March 2021, and received FDA orphan drug designation in April 2022 .
-
The first review!
Time of Update: 2022-05-19
Sales of terminal piracetam injections in Chinese public medical institutions (unit: 10,000 yuan) Source: Minet.
hospital hospital hospital Sales of terminal piracetam injections in Chinese public medical institutions (unit: 10,000 yuan) Source: Minet.
-
For solid tumors!
Time of Update: 2022-05-19
GCC19CART is a GCC-targeting autologous CAR-T therapy product developed for the solid tumor therapy of relapsed, refractory and metastatic colorectal cancer (R/R mCRC) developed by Stance Bio .
References:[1] Gotecca Ecosystem | FDA grants Fast Track designation to Stansay Bio for colorectal cancer CAR-T therapy products.
-
New insight!
Time of Update: 2022-05-18
Recently, researchers from Aarhus University in Denmark published a research article entitled "VEGFA-targeting miR-agshRNAs combine efficacy with specificity and safety for retinal gene therapy" in the journal Molecular Therapy: Nucleic Acids.
VEGFA-targeting miR-agshRNAs combine efficacy with specificity and safety for retinal gene therapy.
-
Yesterday, three pharmaceutical companies released their first-quarter reports, all of which achieved double profits
Time of Update: 2022-05-18
The report shows that during the reporting period, the sales volume of Aibo Medical's core products, "Pu Nuo Ming" series of intraocular lenses and "Pu Nuo Tong" orthokeratology lenses, continued to maintain rapid growth, resulting in a year-on-year increase in operating income and net profit attributable to shareholders of listed companies .
-
Recently, local pharmaceutical companies have successively reviewed a number of large varieties of drugs
Time of Update: 2022-05-18
Data shows that in 2020, the market size of the terminal piracetam injection in China's public medical institutions is close to 2 billion yuan, a year-on-year increase of 37.
-
Multi-pharmaceutical companies issued an announcement: anti-tumor drugs were approved for clinical trials
Time of Update: 2022-05-18
As announced by Sino Biopharmaceuticals, the Group's self-developed anti-tumor Class I new drug "TQB2930" for injection has been approved by the China National Medical Products Administration to conduct drug clinical trials for the treatment of patients with advanced malignant tumors .
-
WuXi Junuo CAR-T product clinical application for new indications was approved
Time of Update: 2022-05-18
On April 20, WuXi Junuo announced that the clinical trial application of Ruikiolanza injection for the treatment of children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) has been approved.
-
It is Henan’s turn to take the lead in the renewal of the national procurement bid, and it is still the alliance of 13 provinces
Time of Update: 2022-05-18
From the perspective of procurement scope, the procurement scope of the 13-province alliance led by Guangdong includes a total of 45 varieties in the first and third batches of domestic production, while the procurement scope led by Henan this time is the second and fourth batches of national procurement, a total of 33 varieties, which are worth mentioning.
-
The new anti-tumor drug introduced by Lee's Big Pharma has been approved for marketing
Time of Update: 2022-05-18
From https:// Good News Group's anti-tumor drug for the treatment of advanced Hodgkin's lymphoma - Natulan® has been accepted by the NMPA, and the application for priority review will be submitted in May.
-
Liantuo Bio has introduced over 200 million US dollars!
Time of Update: 2022-05-18
Retrieved May 12, 2021, From https:// NANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer.
-
On the same day, 3 pharmaceutical companies announced changes in executives
Time of Update: 2022-05-18
It is understood that in Merck China, there have been cases of senior executives returning after leaving office, such as Li Zhengqing, general manager of Merck China R&D Center, who left Merck in 2019 to join Ascletis Pharma as chief medical officer and R&D president of Greater China.
-
The founder of medicine also left?
Time of Update: 2022-05-18
At that time, Zhou Xinhua, who was the scientific director of process development at Amgen in the United States, built a monoclonal antibody drug development and production platform, which is the predecessor of Jiahe Bio .
